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Background: The Centers for Disease Control and Prevention has estimated that atrial fibrillation (AF) affects between 2.7
million and 6.1 million people in the United States. Those who have AF tend to have a much higher stroke risk than others.
Although most individuals with AF benefit from anticoagulation (AC) therapy, a significant majority are hesitant to start it. To
add, providers often struggle in helping patients negotiate the decision to start AC therapy. To assist in the communication between
patients and providers regarding preferences and knowledge about AC therapy, different strategies are being used to try and solve
this problem. In this research study, we will have patients and providers utilize the AFib 2gether app with hopes that it will create
a platform for shared decision making regarding the prevention of stroke in patients with AF receiving AC therapy.
Objective: The aim of our study is to measure several outcomes related to encounters between patients and their cardiology
providers where AFib 2gether is used. These outcomes include usability and perceived usefulness of the app from the perspective
of patients and providers. In addition, we will assess the extent and nature of shared decision making.
Methods: Eligible patients and providers will evaluate the AFib 2gether mobile app for usability and perceived usefulness in
facilitating shared decision making regarding understanding the patient’s risk of stroke and whether or not to start AC therapy.
Both patients and providers will review the app and complete multiple questionnaires about the usability and perceived usefulness
of the mobile app in a clinical setting. We will also audio-record a subset of encounters to assess for evidence of shared decision
making.
Results: Enrollment in the AFib 2gether shared decision-making study is still ongoing for both patients and providers. The first
participant enrolled on November 22, 2019. Analysis and publishing of results are expected to be completed in spring 2021.
Conclusions: The AFib 2gether app emerged from a desire to increase the ability of patients and providers to engage in shared
decision making around understanding the risk of stroke and AC therapy. We anticipate that the AFib 2gether mobile app will
facilitate patient discussion with their cardiologist and other providers. Additionally, we hope the study will help us identify
barriers that providers face when placing patients on AC therapy. We aim to demonstrate the usability and perceived usefulness
of the app with a future goal of testing the value of our approach in a larger sample of patients and providers at multiple medical
centers across the country.
Trial Registration: ClinicalTrials.gov NCT04118270; https://clinicaltrials.gov/ct2/show/NCT04118270
International Registered Report Identifier (IRRID): DERR1-10.2196/21986
(JMIR Res Protoc 2021;10(2):e21986) doi: 10.2196/21986
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Introduction
Atrial fibrillation (AF) and atrial flutter occur in epidemic
proportions in the United States [1-4]. The Centers for Disease
Control and Prevention estimates that AF affects between 2.7
million and 6.1 million people in the United States [5].
Anticoagulation (AC) is the mainstay of therapy, but many
patients are reluctant to start taking anticoagulants [6]. Patients
who have a diagnosis of AF generally have a higher risk of
stroke than the general population [7]. Even among those who
do start AC therapy, many do not persist with the treatment
after bleeding or other setbacks. Providers also struggle with
balancing the risks and benefits of AC therapy. Being able to
determine an optimal decision for each patient is a valuable
goal in stroke prevention. Shared decision making has been
recommended by the American Heart Association (AHA) and
other professional societies as a way to arrive at an optimal
decision, but the usability and perceived usefulness of
conducting shared decision making via an app visit are unclear
[8].
Conducting shared decision-making visits will require several
changes from standard provider-patient interactions. Shared
decision-making visits will help patients and providers make
the best choice in therapy that will fit into a patient’s life. Firstly,
providers do not always draw attention to the fact that there is
a decision to be made and may make the decision for the patient
without soliciting the patient’s preferences. Secondly, providers
do not always inquire about the patient’s preferred treatment
approach, which can create a barrier for shared decision making.
It is also possible that providers may not be knowledgeable or
confident in managing AF patients with the most recently
published guidelines and the advent of direct oral AC therapy
(ie, modern AF management). Conducting AF management
through a shared decision-making process may help in
overcoming the above limitations. Currently, it is unknown how
best to operationalize shared decision making around AC
therapy for AF.
Shared decision-making tools can help patients make informed
decisions with less conflict [9]. The AFib 2gether mobile app,
which was developed by Pfizer Inc in consultation with a
cardiologist (DM), is one potential approach for operationalizing
shared decision making around AC therapy for AF. The app
can provide a platform for a patient to determine their risk of
stroke and identify items for discussion at an upcoming visit
with their provider. The app was designed to support
collaboration during patient visits, which allows for the app to
provide a high-level overview of AF and AC therapy and to
prepare patients to have the tools needed to ask questions of
their providers. The provider can review the answers given by
the patient’s app as well as any questions the patient solicited
in the app for discussion prior to the visit. The goal is that this
interaction will help the patient make a more informed decision
by helping them become more engaged in their health status
and improve their stroke prevention management related to AF.
We have not previously tested the app with patients and
providers for usability and perceived usefulness for clinical
encounters. Therefore, we describe herein our protocol for
testing the app in a clinical setting, including measurement of
the usability of the app and its usefulness during clinical
appointments between patients with AF, who are not currently
prescribed AC therapy, and their cardiology providers. We also
propose a measurement of the extent and nature of shared
decision making that occurs through audio-recording the
encounters facilitated by our app.
Methods
Study Aims
The aim of the AFib 2gether research study is to measure the
usability and perceived usefulness of the shared decision-making
mobile app AFib 2gether from the perspective of patients and
providers. We will also measure patient AC status by chart
review 6 months after their shared decision-making visit to see
if patients started AC therapy. Finally, we will assess the extent
and nature of shared decision making through a review of
audio-recordings of the patient encounters with their providers.
Study Population
Setting
This study will take place at the cardiology practice of an
academic, tertiary care health system in central Massachusetts.
Providers
We will enroll up to 20 cardiology providers practicing at the
University of Massachusetts (UMass) Memorial Healthcare
System in the Ambulatory Care Center (ACC) Cardiology
Clinic.
Patients
We will enroll up to 60 patients who are not receiving AC
therapy, with each provider contributing up to 6 AF patients
with elevated stroke risk. Recruitment will be restricted to
patients aged 18 years and older. To identify patients, we will
use a diagnostic concept grouper within our electronic health
record (EHR) system that follows our inclusion criteria
consistent with AF. Subsequently, patients will be filtered to
retain those patients with CHA2DS2-VASc stroke risk scores
of 2 or greater [8] who were not on AC therapy and had an
upcoming cardiology visit in the next 3 months. The
CHA2DS2-VASc score assigns 1 point for congestive heart
failure, hypertension, age 65 to 74 years, diabetes mellitus,
vascular disease history, and female sex. The score assigns 2
points for age greater than 75 years and for previous stroke or
transient ischemic attack history.
The following participants will be excluded: patients that have
a WATCHMAN device or have had left atrial appendage closure
surgery, patients in hospice or for whom life expectancy is less
than 6 months, and patients with bleeding episodes or falls with
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injury 4 weeks prior to their cardiology appointment.
Additionally, patients with preferred languages other than
English will be excluded from the study because the app AFib
2gether is only available in English. Patients will be excluded
from the study if they are members of vulnerable populations
(ie, pregnant women and prisoners). The eligibility process is
outlined (see Figure 1) to represent how patient eligibility will
be verified before patients consent to participate in the study.
Figure 1. Overview of the provider and patient eligibility process for consent and enrollment in the study.
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A custom query developed by the information technology
department at our institution will be used to identify eligible
patients who have encounters with consenting cardiology
providers in the upcoming 3 months. A manual review of
patients’ charts will be conducted to confirm that a patient was
not receiving AC therapy (eg, from an outside provider,
sometimes documented in scanned notes as opposed to
structured variables).
The research assistant (RA) will start recruiting providers who
had 3 or more patients that fit the study inclusion criteria. Each
provider will then receive a study inquiry email from the RA
to see if they are interested in participating in the study. If the
provider agrees, they will sign the consent form and a letter will
be mailed to their patients. Once enrolled, providers will receive
a link to the secure REDCap (Research Electronic Data
Capture)-based survey [10] to self-administer a questionnaire
(see Multimedia Appendix 1) about their knowledge regarding
AF management.
Additionally, letters signed by the patient’s cardiology provider
along with a fact sheet and Health Insurance Portability and
Accountability Act (HIPAA) authorization form will be mailed
to each eligible patient 1 to 2 weeks prior to the patient’s
appointment. Approximately 5 days later, the RA will call
patients for a follow-up to gauge interest in participating in the
study. For patients who scheduled a visit within 1 week of the
appointment date, messages with study recruitment and consent
materials will be sent to the patients as attachments using the
Epic patient portal. Subsequently, patients will be called in the
next 1 to 2 days to obtain consent. For patients who did not
respond to either of these mechanisms or for patients that were
scheduled within 24 hours of their appointment, our Institutional
Research Board approved the RA to meet and recruit patients,
as feasible, in the waiting room of the cardiology clinic prior
to the patient visits.
Intervention and App Description
Once a patient has provided informed consent to participate,
we will ask them to download the AFib 2gether mobile app
onto their personal smartphone or a family member’s
smartphone or to use the study device for in-person visits. AFib
2gether is a mobile app that may be helpful to foster a shared
decision-making discussion between patients and providers.
The AFib 2gether app may help increase a patient’s
understanding of their risk of stroke due to AF through the
personalized stroke risk calculator, information sheets, videos,
website links, and facts in the app (see Figure 2). In addition,
the app allows patients to select questions about AF and their
stroke risk score to discuss with their health care providers. The
goal of the app is to improve patient understanding; it stands in
distinction to other apps related to assisting providers with
choosing a particular anticoagulant.
For patients recruited at the time of their office visit, the RA
will offer the study smartphone, an Android OS smartphone,
for patient use with the AFib 2gether app predownloaded on
the device or will assist the patient in downloading the app onto
their personal device. Next, the RA will instruct the patient to
put in a study-specific code for the app. Once the patient puts
in the study code, the patient will be able to consent to the app’s
terms and conditions. Once the patient has agreed to the app’s
terms and conditions, the patient may then answer questions on
the app to determine their knowledge of their stroke risk score.
The questions include whether the patient has ever had heart
failure, hypertension, diabetes, stroke, vascular disease, or
previous stroke and what their age and gender are. Once the
participant answers the questions, the app will display their
categories for stroke risk and will allow the participant to select
up to three questions from a list of 13 commonly asked questions
that they may want to discuss with their provider during their
visit based on their risk assessment. Examples of the types of
questions a participant could choose are as follows: Would you
like to know more about your condition? What is the cost of
AC therapy? and What are the benefits of going on AC therapy
to avoid stroke? The participant will be given the option to type
in any additional questions they may have that were not listed
in the app. Lastly, the patient’s risk factors and questions will
then be sent via email to the provider as a PDF document to
review prior to their appointment.
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Figure 2. Advertisement of the AFib 2gether app in the Heart Rhythm Society’s patient toolkit with screenshots of sections of the app.
Data Collection
The RA will administer a modified version of the Mobile App
Rating Scale (MARS) for the purpose of assessing usability
(see Multimedia Appendix 2) [11]. The MARS is a validated
survey that can be used to assess health apps [11]. The modified
questionnaire includes functionality and aesthetics domains that
are similar to the original. We will not include items from the
engagement and entertainment or information domains. We will
include one item from the app subjectivity quality domain,
which is the overall star rating of the app. This followed recent
evidence suggesting the validity of scoring each domain
separately [12]. The RA will wait with the participant until their
visit with the provider begins. Once the cardiology provider is
ready to begin the visit, the RA will then turn on and place the
encrypted recorder—the Olympus DS-7000 (OM Digital
Solutions)—in the room. At this point, the RA will prompt the
provider to review the questions posed by the patient and then
step outside the room and allow the visit to take place without
any further scripting.
At the end of the visit, the RA will collect the voice recorder
and administer questionnaires to both the patient and provider
related to the perceived usefulness of the app following the
technology acceptance model (TAM) [13,14]. Although we did
also consider the unified theory of acceptance and use of
technology 2 (UTAUT2), which unifies the eight theories
including the TAM, we selected the TAM as our theoretical
construct given its applicability to individual patients following
other examples in the literature. Accordingly, we will administer
a questionnaire assessing the patient perceived usefulness of
the mobile app (see Multimedia Appendix 3). For providers,
we will administer a questionnaire assessing the provider
perceived usefulness of the mobile app (see Multimedia
Appendix 4).
Once the patient completes their appointment and
questionnaires, the RA will give the patient a US $25 Amazon
gift card for participating in the study. Providers will be
compensated with a US $200 Amazon gift card after they
complete all study activities.
The UMass Medical School approved our protocol, including
data collection and incentive procedures.
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Modified Study Procedures for COVID-19
During periods when in-person recruitment is not permissible
due to COVID-19 restrictions, we will utilize remote recruitment
and consenting processes. For remote patient recruitment, the
same provider letter will be used, but the fact sheet and HIPAA
authorization will be modified to remove information about the
audio-recording. We will not replace audio-recording with
another method of objectively measuring the extent and type
of shared decision making that occurs. The original HIPAA
authorization form’s wet signature will be replaced with a
process of acknowledgment to disclose protected health
information through the process of agreeing to participate in
the study and phone interview.
Primary Outcomes
Usability
We will group items in the MARS into three domains for
functionality, aesthetics, and overall quality; they will receive
a rating of number of stars out of 5.
Perceived Usefulness
Perceived usefulness will be calculated for patients and
providers based on a custom set of questions derived from the
TAM. More specifically, we will examine their distribution
similar to how we described the usability outcome. We collected
usefulness data on a 5-point Likert scale for simplicity’s sake,
in contrast to the traditional 7-point Likert scale used in TAM
or UTAUT2 literature. In addition, timing will be recorded for
each of the components of the shared decision-making
encounter. The distribution of time required for each activity
will be reviewed.
Shared Decision Making
We will also assess for elements of shared decision making,
including multiple themes covered in established instruments
[15]. These will include a mention that options are available,
evidence that the provider shared stroke and bleeding risk with
the patient, and, most notably, evidence of patient involvement
in the discussion.
Secondary Outcome: Anticoagulation Start
The RA will review each patient’s medical record in our
institution’s EHR system, Epic, to see if the patient started AC
therapy within these 6 months.
Patient and Provider Characteristics
Patient Demographics
Through electronic capture from the data repository associated
with our institution’s EHR system, we will collect age, sex,
race, and ethnicity information.
Comorbidities
From our EHR system, we will also collect the CHA2DS2-VASc
scores using our previously validated algorithm. From manual
chart review, we will also collect information about why the
patient did not previously receive AC therapy, including
potential responses, such as low AF burden, the patient refused,
fall risk, and concomitant aspirin use.
Provider Factors
Through information available from our credentialing office,
we will collect provider age and years in practice in addition to
provider credentials (ie, MD versus NP or PA).
Provider Knowledge
We will measure provider AC therapy decision-making
confidence in several areas, including applying guidelines from
the ACC, the AHA, and the Heart Rhythm Society and assessing
antithrombotic therapy, using CHA2DS2-VASc scores to access
stroke risk, among others. Response options will include
somewhat confident, moderately confident, and very confident.
Analysis
For each domain of usability of the app (ie, MARS items), we
will calculate the mean and standard deviation. For perceived
usefulness, we will group patients into consolidated ordinal
categories based on the Likert response format. We will then
assess for trends in associations and examine associations
between patient characteristics and usability and perceived
usefulness. Where feasible, given low sample size, we will also
calculate t tests or chi-square tests for determining statistical
significance. We will perform all analyses in SAS 9.4 (SAS
Institute Inc) [16]. The UMass Medical School Institutional
Review Board approved our protocol.
Results
This study was registered at ClinicalTrials.gov (NCT04118270).
Enrollment in the AFib 2gether shared decision-making study
is still ongoing for both patients and providers. The first
participant enrolled on November 22, 2019. Analysis and
publishing of results are expected to be completed in spring
2021.
Discussion
We have developed a protocol to measure the usability and
perceived usefulness of a mobile app to facilitate shared decision
making for patients with AF not currently receiving AC therapy.
We also describe the administration of a separate provider
survey that will allow us to measure the association between
provider knowledge and each of these outcomes. Our protocol
provides flexibility to recruit patients during the COVID-19
pandemic or other circumstances where face-to-face interaction
is not possible and where telehealth virtual engagement
strategies are implemented.
With the fast-growing use of online sources for accessing health
information throughout society, a shared decision-making app
or tool for clinical settings has a great potential for impact.
Man-Song-Hing et al developed a decision aid based on a risk
stratification scheme that helped patients and providers make
informed decisions about whether to use warfarin compared
with aspirin for patients with AF [17]. More patients in the
intervention group (n=138, 99%) were able to make definite
choices regarding antithrombotic therapy compared with those
in the control group (n=139, 94%; P=.02). More recently,
Kunneman et al tested a shared decision-making tool that
provided individualized risk estimates of stroke in various AC
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therapy options [18]. Although they did not find a significant
effect on treatment decisions, more clinicians were satisfied
with the encounter in the intervention arm compared with the
standard arm. Neither of the two studies specifically studied the
usability or perceived usefulness of their shared decision-making
tool [17,18].
Overall, there are advantages and disadvantages to using mobile
health apps to conduct shared decision making. Some of the
potential advantages of using a mobile app for shared decision
making include patient empowerment, encouragement of patient
participation in medical decision making, and increased overall
satisfaction [19]. However, we need to balance this against the
potential to increase the anxiety of patients, security concerns,
and lack of accessibility in lower-income areas. The AFib
2gether app provides a convenient and comfortable way for
patients to identify concerns they have about initiating or
resuming AC therapy. The AFib 2gether app provides an
updated and accurate shared decision-making tool that is readily
available to patients and providers through both Google Play
and the Apple App Store, for Android phones and iPhones,
respectively. The AFib 2gether app will provide the tools to
patients and providers to help them make informed decisions
about the best treatment options for the patients. Users of the
app can refer to multiple reliable educational videos, websites,
and facts about AF, stroke, and AC therapy.
We acknowledge multiple limitations to our work. Firstly, the
sample size of both the provider and patient populations are too
small to make any firm conclusions about clinical outcomes,
such as initiating AC therapy. Therefore, we restricted the scope
of the proposed study to verify the usability and perceived
usefulness of the AFib 2gether mobile app, as well as the extent
and nature of shared decision making with the use of the app.
Secondly, we did not have a control population against which
to compare our intervention. In the future, we plan to increase
the sample size and conduct a randomized controlled trial
powered to find a difference in AC therapy starts. Thirdly, some
patients downloaded and explored the app at home prior to the
visit, whereas others, such as those without smartphones, only
reviewed it in the waiting room of the office. We invited the
latter patients to arrive 30 minutes prior to their visit in order
to adequately evaluate the app. Nonetheless, we acknowledge
the variability in usability that might be reported for a patient
who reviewed the app without time constraints at home
compared to a patient who only reviewed the app in the waiting
room. In the future, with a greater sample size, we plan to
measure the discrete effect of the intervention in each situation.
Fourthly, we also acknowledge that prompting by the RA may
have made the app appear more useful than it would have
appeared with no prompting. Given that we are still making
minor modifications to enhance the app, we anticipate being
able to replace the manual prompting with an automated text
message alert reminding providers to review patient responses.
Lastly, a final limitation is that the patients who agree to
participate likely represent a healthier, more technologically
proficient, and potentially more educated population. We did
not collect specific information to gauge patient technology
proficiency, so we cannot compare our population with others.
Future assessment of technology proficiency would help us to
understand the representativeness of the population exposed to
the app versus the general AF population.
In conclusion, we have described the protocol for assessing the
usability and perceived usefulness of a mobile app to facilitate
shared decision making concerning AC therapy in patients with
AF and elevated stroke risk. The AFib 2gether app-based
intervention improves on other shared decision-making
interventions by leveraging a convenient platform (ie, the cell
phone app) and soliciting items for discussion and review before
the patient-provider visit. Although we will not be able to
confirm the ability of the app to demonstrate a significant
increase in AC therapy starts, our study will lay the groundwork
for future efforts to conduct a multicenter, randomized clinical
trial that will be able to elucidate the impact of our mobile app
on clinical outcomes. With the latter road paved, we anticipate
generating significant interest among other researchers
developing app-based interventions to facilitate shared decision
making for AC therapy in AF and similarly challenging
treatment decisions.
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Multimedia Appendix 1
Assessment of provider knowledge and therapeutic approaches for reducing stroke risk in patients with nonvalvular atrial
fibrillation.
[PDF File (Adobe PDF File), 172 KB-Multimedia Appendix 1]
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Provider and patient usability of the mobile app.
[DOCX File , 15 KB-Multimedia Appendix 2]
Multimedia Appendix 3
Questionnaire assessing the patient perceived usefulness of the mobile app.
[DOCX File , 12 KB-Multimedia Appendix 3]
Multimedia Appendix 4
Questionnaire assessing the provider perceived usefulness of the mobile app.
[DOCX File , 12 KB-Multimedia Appendix 4]
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